BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Gan & Lee Launches Third Phase 3 Trial of Once-Monthly GLP-1 Bofanglutide for Long-Term Weight Maintenance

Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of...

November 28, 2025 | News

Sanyou Bio Partners With FatiAbGen to Strengthen Korean Market Presence and Expand Global Biopharma Reach

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and South Korea's FatiAbGen Co., Ltd. jointly announced the signing of a...

November 28, 2025 | News

HKeyBio Expands Its Autoimmune and Allergy R&D Capabilities With HKEY-AIDMD 3.0 Platform Upgrade

The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBi...

November 28, 2025 | News

IASO Bio Achieves Landmark Hong Kong Approval for Fucaso CAR-T Therapy

IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commerciali...

November 28, 2025 | Regulatory

Teijin Pharma to Receive $5M Milestone as Bioprojet Advances Novel Narcolepsy Candidate to Phase 1

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that it will receive in Q4 2025 a milestone paym...

November 28, 2025 | News

The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech

Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...

November 27, 2025 | Analysis

Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

November 26, 2025 | News

Otsuka Advances Centanafadine With FDA Filing To Bring a First in Class ADHD Therapy to Children, Adolescents, and Adults

Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a first-in-class norepinephrine, dop...

November 26, 2025 | News

Pin Therapeutics Begins First Human Study of CK1 Alpha Degrader PIN 5018 for Rare Cancer

Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has...

November 25, 2025 | News

Kelun Biotech Reports Strong Phase Three Success for Sac TMT and Keytruda in First Line Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that the Independent Data Monitoring Committee (IDMC) concluded t...

November 25, 2025 | News

AGC Biologics and AAVantgarde Forge New Partnership to Advance Dual AAV Gene Therapies for Inherited Blindness

Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blindn...

November 24, 2025 | News

Pfizer and Astellas Gain Landmark FDA Approval for PADCEV and Keytruda in Cisplatin Ineligible Muscle Invasive Bladder Cancer

PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of ca...

November 24, 2025 | News

Everest Medicines Begins Global Phase I Trial of EVM14 as First Patient Receives Dose in the United States

The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated ...

November 24, 2025 | News

Henlius Therapy Wins Breakthrough Designation as First Immunotherapy Led Perioperative Regimen for Gastric Cancer

The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer p...

November 21, 2025 | News

Stay Connected